Key GazetteHead-To-Head Analysis: Editas Medicine (EDIT) vs. CRISPR THERAPTC (CRSP)Dispatch TribunalCRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotell… Continue reading
Stem cell therapy, the next-gen way to treat diseases: expertThe HinduStem cell, tissue engineering, and regenerative medicine were potential cash cows for Korea, he said. Knowing that it could not penetrate the multinational drug companies that contro… Continue reading
EurekAlert (press release)Fred Hutch researchers engineer complex immunotherapy that may target relapsing leukemiaEurekAlert (press release)The findings, published online in the journal Blood, provide the basis for launching a first-in-human clinical t… Continue reading
Fred Hutch Researchers Engineer Complex Immunotherapy That May Target Relapsing LeukemiaNewswise (press release)The findings, published online in the journal Blood, provide the basis for launching a first-in-human clinical trial of this new immunothera… Continue reading
Stuck on you: Nanogel capsule helps cardiac stem cells stay in placeNC State NewsCardiac stem cell therapy is a promising treatment for damaged hearts. However, researchers are still working on two major issues with the therapy – how to keep the stem c… Continue reading
Labiotech.eu (blog) |
Shire’s Hemophilia Gene Therapy Boosted by Orphan Drug Designation
Labiotech.eu (blog) The FDA has granted orphan drug designation to Shire’s hemophilia A gene therapy, giving it the boost it needs to catch up with others in the field. Shire specializes in the development of drugs for rare diseases, including hemophilia A – a bleeding … FDA Orphan Drug Designation Granted to Hemophilia Gene Therapy; Clinical Studies to Begin SoonRare Disease Report (blog) Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of …Nasdaq |
|
Immunotherapy in Kidney Cancer
OncLive Martin H. Voss, MD: There’s a longstanding tradition of using immunotherapy in the management of metastatic kidney cancer, and much of the biology really lends itself well to these approaches. We know that this tumor type is often highly infiltrated … |